메뉴 건너뛰기
New England Journal of Medicine
Volumn 377, Issue 9, 2017, Pages 884-885
Bispecific antibody therapy in hemophilia
Author keywords

[No Author keywords available]
Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BISPECIFIC ANTIBODY; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; EMICIZUMAB; NEUTRALIZING ANTIBODY; PROCOAGULANT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8;
EID: 85028546725     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1707802     Document Type: Editorial
Times cited : (9)
References (10)
  • 1
    • 34547436844 scopus 로고    scopus 로고
    • Coagulation factor concentrates: Past, present, and future
    • Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet 2007;370:439-48.
    • (2007) Lancet , vol.370 , pp. 439-448
    • Key, N.S.1    Negrier, C.2
  • 2
    • 84931416208 scopus 로고    scopus 로고
    • Half-life extended factor VIII for the treatment of hemophilia A
    • Tiede A. Half-life extended factor VIII for the treatment of hemophilia A. J Thromb Haemost 2015;13:Suppl 1:S176-S179.
    • (2015) J Thromb Haemost , vol.13 , pp. S176-S179
    • Tiede, A.1
  • 3
    • 33751017726 scopus 로고    scopus 로고
    • The epidemiology of factor VIII inhibitors
    • Hay CRM. The epidemiology of factor VIII inhibitors. Haemophilia 2006;12:Suppl 6:23-8.
    • (2006) Haemophilia , vol.12 , pp. 23-28
    • Hay, C.R.M.1
  • 4
    • 33846185403 scopus 로고    scopus 로고
    • A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: The FEIBA NovoSeven Comparative (FENOC) Study
    • Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007;109:546-51.
    • (2007) Blood , vol.109 , pp. 546-551
    • Astermark, J.1    Donfield, S.M.2    DiMichele, D.M.3
  • 5
    • 84856866914 scopus 로고    scopus 로고
    • The principal results of the International Immune Tolerance Study: A randomized dose comparison
    • Hay CR, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012;119:1335-44.
    • (2012) Blood , vol.119 , pp. 1335-1344
    • Hay, C.R.1    DiMichele, D.M.2
  • 6
    • 0141482007 scopus 로고    scopus 로고
    • Cost of care and quality of life for patients with hemophilia complicated by inhibitors: The COCIS Study Group
    • Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003;102:2358-63.
    • (2003) Blood , vol.102 , pp. 2358-2363
    • Gringeri, A.1    Mantovani, L.G.2    Scalone, L.3    Mannucci, P.M.4
  • 7
    • 85028497303 scopus 로고    scopus 로고
    • Emicizumab prophylaxis in hemophilia A with inhibitors
    • Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017;377: 809-18.
    • (2017) N Engl J Med , vol.377 , pp. 809-818
    • Oldenburg, J.1    Mahlangu, J.N.2    Kim, B.3
  • 8
    • 84971325206 scopus 로고    scopus 로고
    • Factor VIII — Mimetic function of humanized bispecific antibody in hemophilia A
    • Shima M, Hanabusa H, Taki M, et al. Factor VIII — mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med 2016;374:2044-53.
    • (2016) N Engl J Med , vol.374 , pp. 2044-2053
    • Shima, M.1    Hanabusa, H.2    Taki, M.3
  • 9
    • 84955478863 scopus 로고    scopus 로고
    • New products for the treatment of haemophilia
    • Laffan M. New products for the treatment of haemophilia. Br J Haematol 2016;172:23-31.
    • (2016) Br J Haematol , vol.172 , pp. 23-31
    • Laffan, M.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.